

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
January 15, 2013**

**ORDER GRANTING CONFIDENTIAL TREATMENT  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Amgen Inc.**

**File No. 0-12477 - CF#29201**

---

Amgen Inc. submitted an application under Rule 24b-2 of the Exchange Act requesting an extension of prior grants of confidential treatment for information it excluded from the Exhibits to a Form10-Q filed on August 13, 2002 and a 10-K filed March 10, 2003.

Based on representations by Amgen Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

<b>Exhibit</b>	<b>Form</b>	<b>Filed</b>	<b>Confidential Treatment Granted</b>
10.77	10-Q	August 13, 2002	through November 27, 2017
10.87	10-K	March 10, 2003	through November 27, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Laura S. Crotty  
Special Counsel